Evommune disclosed results from a phase 2a clinical trial evaluating its IL-18–targeting fusion protein, EVO301, in patients with moderate to severe atopic dermatitis. The data represent the company’s first major clinical update since it became a public company late last year and were followed by a sharp increase in its share price during premarket trading.
The trial assessed a long-acting intravenous formulation of EVO301 in 70 patients over a 12-week period. Participants received two doses of the drug at the same dose level, administered on Day 1 and Day 28. Of the total study population, 48 patients were assigned to the EVO301 treatment arm, and 22 received a placebo.
According to the results, patients treated with EVO301 achieved a 55% reduction in Eczema Area and Severity Index (EASI) scores at Week 12. In comparison, patients in the placebo group recorded a 22% reduction over the same period. This translated into a 33% placebo-adjusted reduction in absolute EASI score, allowing the study to meet its primary endpoint. Statistically significant differences between the treatment and placebo groups were also observed at Week 4 and Week 8.
Evommune also reported outcomes using the validated Investigator’s Global Assessment for Atopic Dermatitis. At Week 12, 23% of patients receiving EVO301 achieved a score of 0 or 1 on the scale and demonstrated at least a two-point improvement from baseline.
William Blair analysts commented on the results in a note to investors, highlighting the magnitude of the EASI reductions achieved with a nonoptimized dosing approach. They noted that the 33% placebo-adjusted improvement at Week 12 falls within the range reported for marketed biologics, including Regeneron and Sanofi’s Dupixent, which achieved placebo-adjusted reductions of 35% to 36% at Week 16 in phase 3 trials. The analysts also referenced Eli Lilly’s Ebglyss when discussing the Investigator’s Global Assessment outcomes.
“We highlight that the EVO301 phase 2a results are highly encouraging given that patients only received two doses of EVO301 at a single dose level,” the William Blair analysts said.
Following the data release, Evommune’s share price rose 75% in premarket trading on Tuesday, climbing from a Monday closing price of $16.99 to nearly $30. Shares later reached $29.87 during Tuesday morning trading.
Evommune plans to advance EVO301 into a phase 2b trial that will evaluate a subcutaneous formulation of the drug. During a call with analysts, Chief Executive Officer Luis Peña said the next study could explore higher doses, increased dosing frequency, or both, noting that the drug has been well-tolerated to date. He also cited the heterogeneity of atopic dermatitis and the efficacy levels achieved by existing treatments as considerations in trial design.
In addition to atopic dermatitis, Evommune is evaluating EVO301 for other inflammatory conditions, including ulcerative colitis. The company identified initiation of a phase 2 ulcerative colitis trial as a 2026 objective in its IPO documentation. Peña said it is possible the company could initiate a proof-of-concept study sooner rather than later.
Evommune Announces Top‑Line Phase 2a Results
Evommune has released positive top‑line data from its Phase 2a proof‑of‑concept trial evaluating EVO301 in adults with moderate‑to‑severe atopic dermatitis. The study met its primary efficacy endpoint and demonstrated rapid, statistically significant reductions in disease severity compared with placebo over a 12‑week period in a randomized, double‑blind, placebo‑controlled setting. These results highlight the potential of EVO301 as a novel therapeutic option for patients struggling with persistent symptoms despite existing treatments.
Evommune’s EVO301 Efficacy and Safety Highlights
The Phase 2a trial showed that EVO301 achieved significant improvements in the Eczema Area and Severity Index (EASI) at multiple time points, with a 33 % placebo‑adjusted reduction at week 12. Additionally, nearly a quarter of treated patients reached an investigator global assessment score indicating minimal or no disease, while those on placebo did not reach the same thresholds. The safety profile was favorable, with no related serious or severe adverse events reported.
Evommune Plans Phase 2b and Future Research
Following the successful Phase 2a results, Evommune is planning a Phase 2b dose‑ranging trial using a subcutaneous formulation to further optimize dosing and expand the clinical profile of EVO301. The company is also exploring potential additional indications for this therapy, including inflammatory conditions beyond atopic dermatitis, which could broaden the impact of this program if later trials are successful.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
